Combining Ginkgo Leaf Pills and Huperzine A with Nerve Stimulation for Cognitive Impairment After Brain Injury
The Study of Ginkgo Leaf Dropping Pills and Huperzine a Injection Combined with Median Nerve Electrical Stimulation in the Treatment of Cognitive Impairment After Brain Injury
This study is testing if a mix of ginkgo leaf pills, huperzine A injections, and nerve stimulation can help people with memory and thinking problems after a brain injury.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Wanbangde Pharmaceutical Group Co., LTD Industry-sponsored |
| Locations | 1 site (Ganzhou, Jiangxi) |
| Trial ID | NCT06704334 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of a combination treatment involving ginkgo biloba dropping pills, huperzine A injection, and median nerve electrical stimulation in patients suffering from cognitive impairment following brain injury. The study is designed as a randomized, controlled, single-center exploratory trial, focusing on the neuroprotective effects and potential improvements in cognitive function. Participants will be monitored for changes in their cognitive abilities as a result of the interventions.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old with cognitive impairment resulting from brain injury.
Not a fit: Patients with severe underlying diseases, consciousness disorders, or contraindications to the treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly enhance cognitive recovery in patients with brain injury.
How similar studies have performed: While this approach combines established treatments, the specific combination and its effects on cognitive impairment after brain injury are relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Be over 18 years old
* Residual cognitive impairment due to brain injury
* No previous history of brain-related diseases except this one
Exclusion Criteria:
* The patient had severe underlying disease and unstable vital signs
* The patient was complicated with consciousness disorder and could not cooperate with cognitive function assessment ③ Allergic to drugs or contraindications in drug use ④ There are contraindications of median nerve electrical stimulation
Where this trial is running
Ganzhou, Jiangxi
- The Ganzhou City People's Hospital — Ganzhou, Jiangxi, China (Recruiting)
Study contacts
- Study coordinator: Dong Wang
- Email: 2623693068@qq.com
- Phone: 18007076858
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.